These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 28284216)

  • 1. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
    Guo N; Peng Z
    J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
    Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
    Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
    Yang ZJ; Zhao BB; Li L
    J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients.
    Levy T; Weiser R; Boaz M; Ben Shem E; Golan A; Menczer J
    Gynecol Oncol; 2013 Apr; 129(1):165-8. PubMed ID: 23274778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
    Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
    Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
    Palomar Muñoz A; Cordero García JM; Talavera Rubio MDP; García Vicente AM; Pena Pardo FJ; Jiménez Londoño GA; Soriano Castrejón Á; Aranda Aguilar E
    Medicine (Baltimore); 2018 Apr; 97(17):e0098. PubMed ID: 29702969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer.
    Zhang W; Wang L; Xin Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0358. PubMed ID: 29668586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
    Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
    Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([
    Palomar Muñoz A; Cordero García JM; Talavera Rubio P; García Vicente AM; González García B; Bellón Guardia ME; Soriano Castrejón Á; Aranda Aguilar E
    Med Clin (Barc); 2018 Aug; 151(3):97-102. PubMed ID: 29276012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
    Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
    PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
    Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
    J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
    Zou L; He X; Zhang JW
    Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer.
    Krell D; Said Battistino F; Benafif S; Ganegoda L; Hall M; Rustin GJS
    Int J Gynecol Cancer; 2017 Jul; 27(6):1118-1122. PubMed ID: 28333841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer.
    Murakami M; Miyamoto T; Iida T; Tsukada H; Watanabe M; Shida M; Maeda H; Nasu S; Yasuda S; Yasuda M; Ide M
    Int J Gynecol Cancer; 2006; 16 Suppl 1():99-107. PubMed ID: 16515575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.